abstract: INTRODUCTION: The survival for @entity0 with locally advanced, unresectable @entity3 receiving standard of care concomitant chemoradiation remains disappointingly low. A reduction in both local and distant recurrence is needed to improve @entity0 ' outcome. Performing molecular studies on serially collected @entity1 specimens may result in a better selection of therapeutic options. METHODS: We conducted a phase II single-institution trial of two cycles of induction chemotherapy with @entity2 and @entity5 followed by high-dose conformal radiation concomitant with weekly @entity4 and @entity5 in 39 @entity0 . The trial required a dedicated @entity1 biopsy before treatment initiation. In addition, @entity1 biopsies were requested, if safely feasible, before initiation of chemoradiation and 2 months after completion all therapy. RESULTS: Induction chemotherapy was well tolerated, and 38 @entity0 proceeded with chemoradiation. The mean delivered radiation dose was 70.2 Gy, 23 @entity0 received the full dose of 74 Gy, and 19 @entity0 completed all treatment on schedule without dose reductions or delays. Median overall and progression-free survivals were 22.7 and 14.3 months, respectively. A total of 82 procedures, including 46 transthoracic core needle biopsies, were performed. Thirteen @entity0 had all three serial @entity1 biopsies. Three of these procedures resulted in complications that required an intervention; all for the treatment of a biopsy-induced pneumothorax. CONCLUSIONS: We conclude that induction @entity2 / @entity5 followed by concurrent @entity4 / @entity5 with conformal radiation to 74 Gy is safe and tolerable with promising efficacy. We demonstrated that dedicated and serial @entity1 collections are safe, feasible, and acceptable for @entity0 with @entity3 .
  